Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober, Bruce, Paul, Carle, Blauvelt, Andrew, Thaçi, Diamant, Puig, Luis, Lebwohl, Mark, White, Katy, Vanvoorden, Veerle, Deherder, Delphine, Gomez, Natalie Nunez, Eyerich, Kilian
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Thaçi, D, Armstrong, A, Lebwohl, M, Blauvelt, A, Paul, C, Puig, L, Wang, M, Vanvoorden, V, Madden, C, Wiegratz, S, Deherder, D, Gordon, KB
Published in Skin (Milwood, N.Y.) (16.11.2022)
Published in Skin (Milwood, N.Y.) (16.11.2022)
Get full text
Journal Article